Síntomas intestinales en pacientes que reciben inhibidores de bomba de protones (IBP). Resultados de una encuesta multicéntrica en México

American Medical Society National Historic Chemical Landmarks. Tagamet®: Discovery of histamine H2-receptor antagonist [consultado 17 Abr 2017]. Disponible en: http://www.acs.org/content/acs/en/education/whatischemistry/landmark/cimetidinetagamet.htlm Bate, 1990, Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic and histological evaluations, Gut, 31, 968, 10.1136/gut.31.9.968 Thomson, 2010, Safety of the long-term use of proton pump and risk inhibitors, Wrld J Gastroenterol, 16, 2323, 10.3748/wjg.v16.i19.2323 Reiner, 2013, Safety of long-term PPI thereapy, Best Pract Res Clin Gastroenterol, 27, 443, 10.1016/j.bpg.2013.06.001 Rousseau, 2003, Association between pulmonary and digestive infections in patients receiving gastric acid-lowering medications for long-duration, Brain Inj, 17, 885, 10.1080/0269905031000089378 Laheli, 2003, Gastric-acid suppressive therapy and community-acquired respiratory infections, Alimen Pharmacol Ther, 18, 847, 10.1046/j.1365-2036.2003.01744.x Rodríguez, 2009, Acid-suppression drugs and community-acquired pneumonia, Epidemiology, 20, 800, 10.1097/EDE.0b013e3181b5f27d Eom, 2011, Use of acid-suppressive drugs and risk pneumonia: A systematic review and meta-analysis, CMAJ, 183, 310, 10.1503/cmaj.092129 Canani, 2006, Therapy with gastric acidity inhibitors increases trhe risk of acute gastroenteritis and community-acquired pneumonia in children, Pediatrics, 117, e817, 10.1542/peds.2005-1655 García Rodríguez, 2007, Use of acid-suppressing drugs and the risk of gastroenteritis, Clin Gastroenterol Hepatol, 5, 1418, 10.1016/j.cgh.2007.09.010 Leonard, 2007, Systematic review of the risk of enteric infection in patients taking acid suppression, Am J Gastroenterol, 102, 2047, 10.1111/j.1572-0241.2007.01275.x Aseeri, 2008, Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized patients, Am J Gastroenterol, 103, 2308, 10.1111/j.1572-0241.2008.01975.x Linsky, 2010, Proton pump inhibitors and the risk for recurrent Clostridium difficile infection, Arch Intern Med, 170, 772, 10.1001/archinternmed.2010.73 Eun, 2013, PPIS are associated with higher C. difficile infection in critically ill patients compared to H2RA, Un Eur Hastroenterol J, 1, A379 Fried, 1994, Duodenal bacterial overgrowth during treatment in outpatients with omeprazole, Gut, 35, 23, 10.1136/gut.35.1.23 Thorens, 1996, Bacterial overgrowth during treatment with omeprazole compared with cimetidine: A prospective randomized double blind study, Gut, 39, 54, 10.1136/gut.39.1.54 Williams, 2006, Review article: Proton pump inhibitors and bacterial overgrowth, Aliment Pharmacol Ther, 23, 3, 10.1111/j.1365-2036.2006.02707.x Saettone, 2009, Prevalence of small bowel intestinal bacterial overgrowth (SIBO) in chronic proton pump inhibitors users: A pilot case-control study, Dig Liver Dis, 41, S142, 10.1016/S1590-8658(09)60372-8 Zwolinska Wcislo, 2013, Small Intestinal bacterial overgrowth and gastrointestinal symptoms in celiac disease patients receiving proton pump inhibitors, UEG Journal, 1, A579 Jacobs, 2013, Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth, Aliment Pharmacol Ther, 37, 1103, 10.1111/apt.12304 Lo, 2013, Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: A meta-analysis, Clin Gastroentero lHepatol, 11, 483, 10.1016/j.cgh.2012.12.011 Lombardo, 2010, Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy, Clin Gastroenterol Hepatol, 8, 504, 10.1016/j.cgh.2009.12.022 Fujimori, 2015, What are the effects of proton pump inhibitors on the small intestine?, World J Gastroenterol, 21, 6817, 10.3748/wjg.v21.i22.6817 Scarpignato, 2016, Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression, BMC Med, 14, 179, 10.1186/s12916-016-0718-z Iwakiri, 2016, Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015, J Gastroenterol, 51, 751, 10.1007/s00535-016-1227-8 Hood, 2014, Proton pump inhibitor prescribing and costs in a large outpatient clinic, W V Med J, 110, 16 Corleto, 2014, Proton pump inhibitor therapy and potential long-term harm, Curr Opin Endocrinol Diab Obes, 21, 3, 10.1097/MED.0000000000000031 Xie, 2017, Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury, Kidney Int, 91, 1482, 10.1016/j.kint.2016.12.021 Brewster, 2007, Proton pump inhibitors and the kidney: Critical review, Clin Nephrol, 68, 65, 10.5414/CNP68065 Yu, 2017, A review of the novel application and potential adverse effects of proton pump inhibitors, Adv Ther, 10, S12325 Wang, 2017, Proton-pump inhibitor use and the risk of first-time ischemic stroke in the general population: A nationwide population-based study, Am J Gastroenterol, 10, 1038 Schnoll Sussman, 2017, Clinical implications of emerging data on the safety of proton pump inhibitors, Curr Treat Options Gastroenterol, 15, 1, 10.1007/s11938-017-0115-5 Sandler, 2002, The burden of selected digestive disease in the United States, Gastroenterology, 122, 1500, 10.1053/gast.2002.32978 Sperber, 2010, Irritable bowel syndrome and co-morbid gastrointestinal and extra-gastrointestinal functional syndromes, J Neurogastroenterol Motil, 16, 113, 10.5056/jnm.2010.16.2.113 Nastaskin, 2006, Studying the overlap between IBS and GERD: A systematic review of the literature, Dig Dis Sci, 51, 2113, 10.1007/s10620-006-9306-y Schmulson, 2010, Heartburn and other related symptoms are independent of body mass index in irritable bowel syndromes, Rev Esp Enferm Dig, 102, 229, 10.4321/S1130-01082010000400002 De Bortoli, 2013, Overlap of functional heartburn and gastroesophageal reflux disease with irritable bowel syndrome, World J Gastroenterol, 19, 5787, 10.3748/wjg.v19.i35.5787 Choung, 2013, Associations between medication use and functional gastrointestinal disorders: A population-based study, Neurogastroenterol Motil, 25, 10.1111/nmo.12082 Spiegel, 2009, Bacterial overgrowth and irritable bowel syndrome: Unifying hypothesis or a spurious consequence of proton pump inhibitors?, Am J Gastroenterol, 103, 2972, 10.1111/j.1572-0241.2008.01992.x Compare, 2010, Effect of long-term PPI treatment on producing bowel symptoms and SIBO, Eur J Clin Invest, 41, 380, 10.1111/j.1365-2362.2010.02419.x Pica, 2009, Proton pump inhibitors long-term therapy impairs oro-cecal transit time and predisposes to small intestinal bacterial overgrowth, Dig Liver Dis, 41, S21, 10.1016/S1590-8658(09)60053-0 Lebowohl, 2014, Use of proton pump inhibitors and subsequent risk of celiac disease, Dig Liver Dis, 46, 36, 10.1016/j.dld.2013.08.128 Ford, 2009, Small intestinal bacterial overgrowth in irritable bowel syndrome: A systematic review and meta-analysis, Clin Gastroenterol Hepatol, 7, 1279, 10.1016/j.cgh.2009.06.031 Thabane, 2012, Clustering and stability of functional lower gastrointestinal symptom after enteric infection, Neurogastroenterol Motil, 24, 10.1111/j.1365-2982.2012.01898.x Schmulson, 2014, Microbiota, gastrointestinal infections, low grade inflammation, and antibiotic therapy in irritable bowel syndrome (IBS): An evidence-based review, Rev Gastroenterol Mex, 79, 96 Clooney, 2016, A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors, Aliment Pharmacol Ther, 43, 974, 10.1111/apt.13568 Thompson, 2016, Effect of a proton pump inhibitor deprescribing guideline on drug usage and costs in long-term care, J Am Med Dir Assoc, 17, 673, 10.1016/j.jamda.2016.04.020 Rezaie, 2017, Hydrogen and methane-based breath testing in gastrointestinal disorders: The North American Consensus, Am J Gastroenterol, 112, 775, 10.1038/ajg.2017.46